JP2007538108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007538108A5 JP2007538108A5 JP2007527588A JP2007527588A JP2007538108A5 JP 2007538108 A5 JP2007538108 A5 JP 2007538108A5 JP 2007527588 A JP2007527588 A JP 2007527588A JP 2007527588 A JP2007527588 A JP 2007527588A JP 2007538108 A5 JP2007538108 A5 JP 2007538108A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- administered
- subject
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 229960004641 rituximab Drugs 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57297304P | 2004-05-20 | 2004-05-20 | |
| US60/572,973 | 2004-05-20 | ||
| US63538004P | 2004-12-10 | 2004-12-10 | |
| US60/635,380 | 2004-12-10 | ||
| US67128105P | 2005-04-14 | 2005-04-14 | |
| US60/671,281 | 2005-04-14 | ||
| US68044705P | 2005-05-12 | 2005-05-12 | |
| US60/680,447 | 2005-05-12 | ||
| PCT/US2005/019126 WO2005113001A1 (en) | 2004-05-20 | 2005-05-20 | Methods of treating cancer using il-21 and monoclonal antibody therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011284589A Division JP2012102122A (ja) | 2004-05-20 | 2011-12-27 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007538108A JP2007538108A (ja) | 2007-12-27 |
| JP2007538108A5 true JP2007538108A5 (enExample) | 2008-07-10 |
| JP4982373B2 JP4982373B2 (ja) | 2012-07-25 |
Family
ID=34971701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527588A Expired - Fee Related JP4982373B2 (ja) | 2004-05-20 | 2005-05-20 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
| JP2011284589A Ceased JP2012102122A (ja) | 2004-05-20 | 2011-12-27 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011284589A Ceased JP2012102122A (ja) | 2004-05-20 | 2011-12-27 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US20050265966A1 (enExample) |
| EP (4) | EP2431050A1 (enExample) |
| JP (2) | JP4982373B2 (enExample) |
| KR (1) | KR101236177B1 (enExample) |
| CN (2) | CN103127502A (enExample) |
| AU (1) | AU2005245031B2 (enExample) |
| BR (1) | BRPI0511187A (enExample) |
| CA (1) | CA2566745A1 (enExample) |
| CY (1) | CY1113287T1 (enExample) |
| DK (1) | DK1758610T3 (enExample) |
| ES (1) | ES2390278T3 (enExample) |
| IL (1) | IL179099A (enExample) |
| PL (1) | PL1758610T3 (enExample) |
| PT (1) | PT1758610E (enExample) |
| WO (1) | WO2005113001A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| WO2005113001A1 (en) * | 2004-05-20 | 2005-12-01 | Zymogenetics, Inc. | Methods of treating cancer using il-21 and monoclonal antibody therapy |
| US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
| CN101553501A (zh) | 2006-10-26 | 2009-10-07 | 诺沃-诺迪斯克有限公司 | Il-21变种 |
| KR100902340B1 (ko) * | 2007-08-02 | 2009-06-12 | 한국생명공학연구원 | Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법 |
| US8506933B2 (en) * | 2007-11-30 | 2013-08-13 | Msdx, Inc. | Methods of detecting a neurological condition via analysis of circulating phagocytes |
| CA2770680A1 (en) * | 2009-08-10 | 2011-02-17 | Msdx, Inc. | Methods of detecting responses to therapies using perforin levels |
| EP2504699A1 (en) * | 2009-11-27 | 2012-10-03 | MSDX, Inc. | Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition |
| US8673309B2 (en) | 2011-02-11 | 2014-03-18 | Msdx, Inc. | Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 |
| WO2013109904A1 (en) * | 2012-01-19 | 2013-07-25 | University Of Miami | Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| KR101453462B1 (ko) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| MA39821B1 (fr) * | 2014-04-08 | 2020-09-30 | Boston Pharmaceuticals Inc | Molécules de liaison spécifiques de l'il-21 et leurs utilisations |
| KR20160120157A (ko) * | 2015-04-07 | 2016-10-17 | 주식회사 메드팩토 | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
| US20200016200A1 (en) * | 2016-10-03 | 2020-01-16 | Baylor College Of Medicine | Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies |
| WO2019055938A1 (en) * | 2017-09-15 | 2019-03-21 | Beckman Coulter, Inc. | FLOW-BASED DOSINGS FOR THERAPEUTIC AGENTS |
| KR102265437B1 (ko) * | 2017-11-24 | 2021-06-15 | 의료법인 성광의료재단 | Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0325224B1 (en) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| KR101023367B1 (ko) * | 1998-08-11 | 2011-03-18 | 바이오겐 아이덱 인크. | Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| EP1189931B1 (en) * | 1999-07-02 | 2006-06-21 | Genentech, Inc. | Peptide compounds that bind her2 |
| IT1311703B1 (it) | 1999-07-23 | 2002-03-19 | Sipa Spa | Impianto ad alta efficienza di soffiaggio di preforme |
| WO2001077171A2 (en) | 2000-04-05 | 2001-10-18 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
| US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| EP1463524A4 (en) | 2001-12-07 | 2005-02-09 | Chiron Corp | THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| IL164287A0 (en) * | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| CA2487133A1 (en) * | 2002-06-07 | 2003-12-18 | Zymogenetics, Inc. | Use of il-21 in cancer and other therapeutic applications |
| EP1572131B1 (en) * | 2002-10-08 | 2016-07-06 | Immunomedics, Inc. | Antibody therapy |
| US20070092485A1 (en) * | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
| JP4664684B2 (ja) * | 2002-12-13 | 2011-04-06 | ザイモジェネティクス， インコーポレイテッド | 原核生物宿主におけるｉｌ−２１の生産 |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| MXPA06004199A (es) * | 2003-10-17 | 2006-06-28 | Novo Nordisk As | Terapia en combinacion. |
| WO2005113001A1 (en) * | 2004-05-20 | 2005-12-01 | Zymogenetics, Inc. | Methods of treating cancer using il-21 and monoclonal antibody therapy |
| PT1814580T (pt) * | 2004-11-24 | 2016-11-11 | Hutchinson Fred Cancer Res | Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais |
-
2005
- 2005-05-20 WO PCT/US2005/019126 patent/WO2005113001A1/en not_active Ceased
- 2005-05-20 BR BRPI0511187-0A patent/BRPI0511187A/pt not_active IP Right Cessation
- 2005-05-20 CN CN2013100575165A patent/CN103127502A/zh active Pending
- 2005-05-20 CN CN2011101079712A patent/CN102188704B/zh not_active Expired - Fee Related
- 2005-05-20 PT PT05756320T patent/PT1758610E/pt unknown
- 2005-05-20 US US11/134,489 patent/US20050265966A1/en not_active Abandoned
- 2005-05-20 AU AU2005245031A patent/AU2005245031B2/en not_active Ceased
- 2005-05-20 EP EP11184743A patent/EP2431050A1/en not_active Withdrawn
- 2005-05-20 ES ES05756320T patent/ES2390278T3/es not_active Expired - Lifetime
- 2005-05-20 CA CA002566745A patent/CA2566745A1/en not_active Abandoned
- 2005-05-20 DK DK05756320.7T patent/DK1758610T3/da active
- 2005-05-20 PL PL05756320T patent/PL1758610T3/pl unknown
- 2005-05-20 EP EP05756320A patent/EP1758610B1/en not_active Expired - Lifetime
- 2005-05-20 EP EP11184922A patent/EP2428216A3/en not_active Withdrawn
- 2005-05-20 EP EP11184521A patent/EP2425847A1/en not_active Withdrawn
- 2005-05-20 KR KR1020067026277A patent/KR101236177B1/ko not_active Expired - Fee Related
- 2005-05-20 JP JP2007527588A patent/JP4982373B2/ja not_active Expired - Fee Related
-
2006
- 2006-10-06 US US11/539,511 patent/US20070178063A1/en not_active Abandoned
- 2006-10-06 US US11/539,479 patent/US20070048264A1/en not_active Abandoned
- 2006-10-06 US US11/539,493 patent/US20070122382A1/en not_active Abandoned
- 2006-11-07 IL IL179099A patent/IL179099A/en not_active IP Right Cessation
-
2008
- 2008-10-14 US US12/250,911 patent/US20090087404A1/en not_active Abandoned
-
2009
- 2009-05-19 US US12/468,516 patent/US20090269304A1/en not_active Abandoned
-
2010
- 2010-06-29 US US12/826,099 patent/US20110300098A1/en not_active Abandoned
- 2010-11-17 US US12/947,957 patent/US20110086004A1/en not_active Abandoned
-
2011
- 2011-12-27 JP JP2011284589A patent/JP2012102122A/ja not_active Ceased
-
2012
- 2012-09-28 CY CY20121100888T patent/CY1113287T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007538108A5 (enExample) | ||
| US20240009196A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| Mikulska et al. | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52) | |
| TWI784983B (zh) | 可活化之抗ctla-4抗體及其用途 | |
| CN104379602B (zh) | 具有条件活性的抗表皮生长因子受体抗体及其使用方法 | |
| CA2549652C (en) | Cd40 antibody formulation and methods | |
| EP3227342B1 (en) | Proteinaceous heterodimer and use thereof | |
| JP6282745B2 (ja) | 修飾抗上皮成長因子受容体抗体およびその使用法 | |
| JP2013539352A5 (enExample) | ||
| AU2022202800B2 (en) | Combinations and uses thereof | |
| JP2020504723A5 (enExample) | ||
| CN102216332A (zh) | 抗-cs1抗体用于治疗罕见淋巴瘤的用途 | |
| JP2009533367A5 (enExample) | ||
| JP2011507932A5 (enExample) | ||
| JP2009541492A5 (enExample) | ||
| WO2017161206A1 (en) | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use | |
| JP2009518441A5 (enExample) | ||
| CN112839962A (zh) | 用于治疗癌症的抗mertk抗体 | |
| JP2015517511A (ja) | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| EP3658584A1 (en) | Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody | |
| CN111973739A (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
| Zhou et al. | Mechanism of action for therapeutic antibodies | |
| JP2024509944A (ja) | 抗体の新規の組み合わせ及びその使用 | |
| JPWO2023164143A5 (enExample) |